A WAK Technologies has signed an agreement with Baxter International Inc. to develop wearable dialysis technology. The agreement lets AWAK continue developing its investigational peritoneal dialysis-based automated wearable artificial kidney, the company said.
AWAK Technologies is a research-focused, medical technology company dedicated to the development and commercialization of sorbent-based dialysis regeneration technology.
“Our agreement with Baxter is part of our overall strategy to bring innovative technologies for dialysis treatment to market that include collaborations and licensing agreements with academia including the University of California, Los Angeles (UCLA) and Temasek Polytechnic, Singapore, as well as working cooperatively with government agencies in the United States and Singapore; such as the U.S. Veteran Affairs Innovation Initiative (VAi2), SPRING Singapore and International Enterprise (IE) Singapore,” said NEO Kok-Beng, President & CEO of AWAK Technologies.
The agreement will provide Baxter with exclusive global manufacturing and a distribution license for AWAK’s investigational peritoneal dialysis-based automated wearable artificial kidney, a minority ownership stake in the company, and the option to purchase additional equity in the company.
